Vir Biotechnology: Evercore ISI Sees 122% Price Potential Referencing the Differentiated Pipeline and Cash Position

Vir Biotechnology (VIR) is a biopharmaceutical company specializing in the development of therapies and vaccines against severe infectious diseases. The company employs a wide range of technologies, including antibody platforms, to neutralize pathogens such as viruses. Its research focuses on diseases like hepatitis B, HIV, and influenza, as well as emerging pathogens. Vir's core approach is to enhance the human immune system to combat infections. The company has formed partnerships with major pharmaceutical firms in the past to accelerate the...